Your browser doesn't support javascript.
loading
Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.
Yao, Lan-Qing; Chen, Zheng-Liang; Feng, Zi-Han; Diao, Yong-Kang; Li, Chao; Sun, Hai-Ying; Zhong, Jian-Hong; Chen, Ting-Hao; Gu, Wei-Min; Zhou, Ya-Hao; Zhang, Wan-Guang; Wang, Hong; Zeng, Yong-Yi; Wu, Han; Wang, Ming-Da; Xu, Xin-Fei; Pawlik, Timothy M; Lau, Wan Yee; Shen, Feng; Yang, Tian.
Afiliación
  • Yao LQ; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Chen ZL; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Feng ZH; Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
  • Diao YK; Department of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Li C; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Sun HY; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Zhong JH; Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Chen TH; Department of General Surgery, Ziyang First People's Hospital, Ziyang, Sichuan, China.
  • Gu WM; The First Department of General Surgery, The Fourth Hospital of Harbin, Harbin, Heilongjiang, China.
  • Zhou YH; Department of Hepatobiliary Surgery, Pu'er People's Hospital, Pu'er City, Yunnan, China.
  • Zhang WG; Department of Hepatic Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
  • Wang H; Department of General Surgery, Liuyang People's Hospital, Changsha, Hunan, China.
  • Zeng YY; Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, China.
  • Wu H; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Wang MD; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Xu XF; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Pawlik TM; Department of Surgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
  • Lau WY; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
  • Shen F; Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China.
  • Yang T; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China. fengshensmmu@gmail.com.
Ann Surg Oncol ; 2022 Feb 22.
Article en En | MEDLINE | ID: mdl-35192156
ABSTRACT

BACKGROUND:

A potentially curative hepatic resection is the optimal treatment for hepatocellular carcinoma (HCC), but most HCCs, even at an early stage, eventually recur after resection. This study investigates clinical features of initial recurrence and long-term prognosis of patients with recurrence after curative resection for early-stage HCC. PATIENTS AND

METHODS:

From a multicenter database, patients who underwent curative hepatic resection for early-stage HCC [Barcelona Clinic Liver Cancer (BCLC) stage 0/A] were extracted. Time to initial recurrence, patterns of initial recurrence, and treatment modalities for recurrent tumors were investigated. Univariate and multivariate analysis were used to identify independent risks associated with postoperative recurrence, as well as post-recurrence survival (PRS) for patients with recurrence.

RESULTS:

Among 1424 patients, 679 (47.7%) developed recurrence at a median follow-up of 54.8 months, including 408 (60.1%) early recurrence (≤ 2 years after surgery) and 271 (39.9%) late recurrence (> 2 years). Independent risks of postoperative recurrence included cirrhosis, preoperative alpha-fetoprotein level > 400 ug/L, tumor size > 5 cm, multiple tumors, satellites, microvascular invasion, and intraoperative blood transfusion. Multivariate analysis revealed that receiving irregular recurrence surveillance, initial tumor beyond Milan criteria, early recurrence, BCLC stage B/C of the recurrent tumor, and noncurative treatments were independently associated with poorer PRS.

CONCLUSIONS:

Nearly half of patients with early-stage HCC experienced recurrence after resection. Understanding recurrence risks may help identify patients at high risk of recurrence who may benefit from future adjuvant therapies. Meaningful survival even after recurrence can still be achieved by postoperative regular surveillance and curative treatment.

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article